|
1
|
Perou CM, Sørlie T, Eisen MB, et al:
Molecular portraits of human breast tumours. Nature. 406:747–752.
2000. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Dent R, Trudeau M, Pritchard KI, et al:
Triple-negative breast cancer: clinical features and patterns of
recurrence. Clin Cancer Res. 13:4429–4434. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bauer KR, Brown M, Cress RD, et al:
Descriptive analysis of estrogen receptor (ER)-negative,
progesterone receptor (PR)-negative and HER2-negative invasive
breast cancer, the so-called triple-negative phenotype: a
population-based study from the California cancer Registry. Cancer.
109:1721–1728. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Charfare H, Limongelli S and Purushotham
AD: Neoadjuvant chemotherapy in breast cancer. Br J Surg. 92:14–23.
2005. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Fisher B, Bryant J, Wolmark N, et al:
Effect of preoperative chemotherapy on the outcome of women with
operable breast cancer. J Clin Oncol. 16:2672–2685. 1998.PubMed/NCBI
|
|
6
|
Wolmark N, Wang J, Mamounas E, et al:
Preoperative chemotherapy in patients with operable breast cancer:
nine-year results from National Surgical Adjuvant Breast and Bowel
Project B-18. J Natl Cancer Inst Monogr. 96–102. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bear HD, Anderson S, Smith RE, et al:
Sequential preoperative or postoperative docetaxel added to
preoperative doxorubicin plus cyclophosphamide for operable breast
cancer: National Surgical Adjuvant Breast and Bowel Project
Protocol B-27. J Clin Oncol. 24:2019–2027. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Heys SD, Sarkar T and Hutcheon AW: Primary
docetaxel chemotherapy in patients with breast cancer: impact on
response and survival. Breast Cancer Res Treat. 90:169–185. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Houssami N, Macaskill P, von Minckwitz G,
Marinovich ML and Mamounas E: Meta-analysis of the association of
breast cancer subtype and pathologic complete response to
neoadjuvant chemotherapy. Eur J Cancer. 48:3342–3354. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhou B, Xie F, Wang S and Yang D: Response
and prognosis of taxanes and anthracyclines neoadjuvant
chemotherapy in patients with triple-negative breast cancer.
Zhongguo Aizheng Zazhi. 19:129–132. 2009.[(In Chinese)].
|
|
11
|
Kong X, Moran MS, Zhang N, et al:
Meta-analysis confirms achieving pathological complete response
after neoadjuvant chemotherapy predicts favourable prognosis for
breast cancer patients. Eur J Cancer. 47:2084–2090. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Li XR, Liu M, Zhang YJ, et al: CK5/6,
EGFR, Ki-67, cyclin D1 and nm23-H1 protein expressions as
predictors of pathological complete response to neoadjuvant
chemotherapy in triple-negative breast cancer patients. Med Oncol.
28:(Suppl 1). S129–S134. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang G, Xie W, Xu L, Liu Z and Xie X:
Predictors of neoadjuvant chemotherapy for triple-negative breast
cancer: a meta-analysis with 723 cases. Chinese-German J Clin
Oncol. 12:15–19. 2013. View Article : Google Scholar
|
|
14
|
Livasy CA, Perou CM, Karaca G, et al:
Identification of a basal-like subtype of breast ductal carcinoma
in situ. Hum Pathol. 38:197–204. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sun ZK, Ma XT, Wu YD, et al: Response and
Long-Term Effect of Patients with Triple-Negative Breast Cancer
Receiving Neo-Adjuvant Anthracycline-Based Chemotherapy. Clin Oncol
Cancer Res. 6:197–202. 2009. View Article : Google Scholar
|
|
16
|
Wang J and Gao R: Relationship among
clinical characteristics, response and prognosis of neoadjuvant
chemotherapy in patients with triple negative breast cancer. Zhong
Liu Yan Jiu Yu Lin Chuang. 22:833–836. 2010.[(In Chinese)].
|
|
17
|
Jia H, Wu J, Li S, Gu R and Su F: Curative
effects and prognostic evaluation on neoadjuvant chemotherapy of
epirubicin combined with docetaxel for treating triple negative
breast cancer. Ling Nan Xian Dai Lin Chuang Wai Ke. 12:261–265.
2012.[(In Chinese)].
|
|
18
|
Bidard FC, Matthieu MC, Chollet P, et al:
p53 status and efficacy of primary anthracyclines/alkylating
agent-based regimen according to breast cancer molecular classes.
Ann Oncol. 19:1261–1265. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chang HR, Glaspy J, Allison MA, et al:
Differential response of triple-negative breast cancer to a
docetaxel and carboplatin-based neoadjuvant treatment. Cancer.
116:4227–4237. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Darb-Esfahani S, Loibl S, Müller BM, et
al: Identification of biology-based breast cancer types with
distinct predictive and prognostic features: role of steroid
hormone and HER2 receptor expression in patients treated with
neoadjuvant anthracycline/taxane-based chemotherapy. Breast Cancer
Res. 11:R692009. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Fisher CS, Ma CX, Gillanders WE, et al:
Neoadjuvant chemotherapy is associated with improved survival
compared with adjuvant chemotherapy in patients with
triple-negative breast cancer only after complete pathologic
response. Ann Surg Oncol. 19:253–258. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Frasci G, Comella P, Rinaldo M, et al:
Preoperative weekly cisplatin-epirubicin-paclitaxel with G-CSF
support in triple-negative large operable breast cancer. Ann Oncol.
20:1185–1192. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Keam B, Im SA, Lee KH, et al: Ki-67 can be
used for further classification of triple negative breast cancer
into two subtypes with different response and prognosis. Breast
Cancer Res. 13:R222011. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Li J, Gonzalez-Angulo AM, Allen PK, et al:
Triple-negative subtype predicts poor overall survival and high
locoregional relapse in inflammatory breast cancer. Oncologist.
16:1675–1683. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Liedtke C, Mazouni C, Hess KR, et al:
Response to neoadjuvant therapy and long-term survival in patients
with triple-negative breast cancer. J Clin Oncol. 26:1275–1281.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Masuda H, Masuda N, Kodama Y, et al:
Predictive factors for the effectiveness of neoadjuvant
chemotherapy and prognosis in triple-negative breast cancer
patients. Cancer Chemother Pharmacol. 67:911–917. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Medioni J, Huchon C, Le Frere-Belda MA, et
al: Neoadjuvant dose-dense gemcitabine plus docetaxel and
vinorelbine plus epirubicin for operable breast cancer: improved
prognosis in triple-negative tumors. Drugs R D. 11:147–157. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ono M, Tsuda H, Shimizu C, et al:
Tumor-infiltrating lymphocytes are correlated with response to
neoadjuvant chemotherapy in triple-negative breast cancer. Breast
Cancer Res Treat. 132:793–805. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Tang Y, Zhu L, Li Y, et al: Overexpression
of epithelial growth factor receptor (EGFR) predicts better
response to neo-adjuvant chemotherapy in patients with
triple-negative breast cancer. J Transl Med. 10:(Suppl 1). S42012.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wu J, Li S, Jia W and Su F: Response and
prognosis of taxanes and anthracyclines neoadjuvant chemotherapy in
patients with triple-negative breast cancer. J Cancer Res Clin
Oncol. 137:1505–1510. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yoo C, Ahn JH, Jung KH, et al: Impact of
immunohistochemistry-based molecular subtype on chemosensitivity
and survival in patients with breast cancer following neoadjuvant
chemotherapy. J Breast Cancer. 15:203–210. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Smith IC, Heys SD, Hutcheon AW, et al:
Neoadjuvant chemotherapy in breast cancer: significantly enhanced
response with docetaxel. J Clin Oncol. 20:1456–1466. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Sirohi B, Arnedos M, Popat S, et al:
Platinum-based chemotherapy in triple-negative breast cancer. Ann
Oncol. 19:1847–1852. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
De Laurentiis M, Cianniello D, Caputo R,
et al: Treatment of triple negative breast cancer (TNBC): current
options and future perspectives. Cancer Treat Rev. 36:(Suppl 3).
S80–S86. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
O'Shaughnessy J, Osborne C, Pippen JE, et
al: Iniparib plus chemotherapy in metastatic triple-negative breast
cancer. N Engl J Med. 364:205–214. 2011. View Article : Google Scholar : PubMed/NCBI
|
